Differentiated Thyroid Carcinoma: The New UICC 6<sup>th</sup> Edition TNM Classification System in a Retrospective Analysis of 169 Patients

Döbert, Natascha; Menzel, Christian; Oeschger, Sabine; Grünwald, Frank

doi:10.1089/105072504322783867

Cited by 45 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the literature, there are different age standards for classification. 2,4 According to latest standard of the Union Internationale Contre le Cancer (UICC) for differentiated thyroid carcinoma, 11 prognosis differs significantly by age at approximately 45 years. Therefore, we classified patients by age younger than 45 years and 45 years of age or older.…”

Section: Discussionmentioning

confidence: 99%

Association of sonographically detected calcification with thyroid carcinoma

Wang¹,

Xu²,

Ge³

et al. 2006

Head Neck

View full text Add to dashboard Cite

The detection of calcification on ultrasonography should increase the clinical index of suspicion for thyroid carcinoma and alert the physician. FSP calcification is valuable and has a very high specificity for predicting thyroid carcinoma, particularly for those younger than 45 years old or with calcified regional lymph nodes. To increase the sensitivity for the diagnosis of thyroid carcinoma, tests such as fine-needle aspiration cytology should also be performed. The use of these modalities could result in earlier detection of thyroid carcinoma. The use of ultrasound to detect calcification and FSP calcification is as efficient as thyroid papillary macrocarcinoma in predicting microcarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of sonographically detected calcification with thyroid carcinoma

Wang¹,

Xu²,

Ge³

et al. 2006

Head Neck

View full text Add to dashboard Cite

show abstract

“…Clinical staging of thyroid cancer was classified according to the Tumor-node-metastasis (TNM) classification (VI Edition; Dobert et al 2004). Persistent disease was evaluated in 118 patients, with a 2-to 4-year follow-up.…”

Section: Study Design Specimen and Information Collectionmentioning

confidence: 99%

BRAF(V600E) mutation and the biology of papillary thyroid cancer

Frasca¹,

Nucera²,

Pellegriti³

et al. 2008

Endocrine Related Cancer

211

170

View full text Add to dashboard Cite

“…Demographic data of these patients (including sex, age, presence or absence of an associated lymphoid thyroiditis, TNM status, and histological subtype of papillary thyroid carcinoma) are reported in Table 1. The new UICC 6th edition TNM classification system of malignant tumours was used for classifying the anatomical extent of malignant disease and patients' stage (25). Twelve patients had benign adenomas and 14 had a hyperplastic goitre.…”

Section: Subjectsmentioning

confidence: 99%

Platelet-activating factor and human thyroid cancer

Denizot¹,

Chianea²,

Labrousse³

et al. 2005

eur j endocrinol

View full text Add to dashboard Cite

Objective: Platelet-activating factor (PAF) is a pro-inflammatory and angiogenic lipid mediator involved in several types of cancer in humans. The levels of PAF, lyso-PAF (the PAF precursor), phospholipase A 2 activity (PLA 2 , the enzymatic activity implicated in lyso-PAF formation) and acetylhydrolase activity (AHA, the PAF-degrading enzyme) were investigated in various diseased thyroid tissues. Subjects: Control and diseased tissue of patients with a hyperplastic goitre (n ¼ 14), a benign adenoma (n ¼ 12) and a papillary thyroid carcinoma (n ¼ 15) were investigated. Results: PAF receptor transcripts were found in the human thyroid tissue. PAF, lyso-PAF, PLA 2 and AHA were present in control thyroid tissues, their levels being significantly correlated with each other, suggesting tiny regulations of the PAF metabolic pathways inside the thyroid gland. PAF, lyso-PAF, PLA 2 and AHA levels remained unchanged in diseased tissues of patients with a hyperplastic goitre, a benign adenoma and a papillary thyroid carcinoma. No difference was found between PAF, lyso-PAF, PLA 2 and AHA levels with respect to the TNM tumour status and the histological subtype of papillary thyroid carcinoma. No correlation was found between tissue PAF levels and those of vascular endothelial growth factor and basic fibroblast growth factor, two angiogenic growth factors involved in thyroid cancer and that mediate their effect through PAF release in breast and colorectal cancer. Conclusion: PAF, PAF receptor transcripts and the enzymatic activities implicated in PAF production and degradation are present in the thyroid gland. While the physiological role of PAF is presently unknown in thyroid physiology, this study highlights no evidence for a potentially important role of PAF during human thyroid cancer, a result that markedly differs from breast and colorectal ones.European Journal of Endocrinology 153 31-40

show abstract

Differentiated Thyroid Carcinoma: The New UICC 6^th Edition TNM Classification System in a Retrospective Analysis of 169 Patients

Cited by 45 publications

References 14 publications

Association of sonographically detected calcification with thyroid carcinoma

Association of sonographically detected calcification with thyroid carcinoma

BRAF(V600E) mutation and the biology of papillary thyroid cancer

Platelet-activating factor and human thyroid cancer

Contact Info

Product

Resources

About

Differentiated Thyroid Carcinoma: The New UICC 6th Edition TNM Classification System in a Retrospective Analysis of 169 Patients

Cited by 45 publications

References 14 publications

Association of sonographically detected calcification with thyroid carcinoma

Association of sonographically detected calcification with thyroid carcinoma

BRAF(V600E) mutation and the biology of papillary thyroid cancer

Platelet-activating factor and human thyroid cancer

Contact Info

Product

Resources

About

Differentiated Thyroid Carcinoma: The New UICC 6^th Edition TNM Classification System in a Retrospective Analysis of 169 Patients